Triple
T22693019
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | JEWELFISH |
E561098
|
entity |
| Predicate | includesPriorTherapy |
P138411
|
FINISHED |
| Object | nusinersen |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nusinersen | Statement: [JEWELFISH, includesPriorTherapy, nusinersen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: nusinersen Context triple: [JEWELFISH, includesPriorTherapy, nusinersen]
-
A.
Spinraza
chosen
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
C.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
-
D.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
E.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: includesPriorTherapy Context triple: [JEWELFISH, includesPriorTherapy, nusinersen]
-
A.
hasSubsequentTreatment
Indicates that one treatment occurs after and in continuation of another treatment in a temporal sequence.
-
B.
previouslyCovered
Indicates that the subject has already been addressed, discussed, or dealt with at an earlier time or in a prior context.
-
C.
typeOfAdvancedTherapiesAssessed
Indicates that an entity has evaluated or examined specific kinds of advanced therapies (such as gene, cell, or tissue-based treatments).
-
D.
hasPriorHistory
chosen
Indicates that an entity has a previously recorded occurrence, condition, or involvement relevant to the current context.
-
E.
previouslyAdmitted
Indicates that an entity has already been admitted or accepted at an earlier time prior to the current reference point.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789ba0148190891781d05ec64f3c |
completed | April 29, 2026, 3:18 a.m. |
| PD | Predicate disambiguation | batch_69ee62b2259c819091ed1387a748b9f3 |
completed | April 26, 2026, 7:08 p.m. |
Created at: April 17, 2026, 3:13 p.m.